Secure Telehealth System Combines Tetherless Pulse Oximetry with a Remote Data Capture, Patient Surveillance, and Care Flow Platform

IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) announced today the full market release of Masimo SafetyNet™, an innovative, economically scalable cloud-based patient management solution designed to help clinicians care for patients remotely in hospital settings and in non-traditional settings and circumstances. Successfully piloted at leading institutions like University Hospitals (UH) in Cleveland and St. Luke’s University Health Network (St. Luke’s) in Pennsylvania and New Jersey, Masimo SafetyNet is now available worldwide to help clinicians and public health officials combat the global COVID-19 pandemic.


On Wednesday, April 15 at 8:00 am PDT, Masimo and University Hospitals will jointly host a public webinar in which Dr. Peter Pronovost and his colleagues at University Hospitals join Masimo Founder and CEO Joe Kiani to discuss Masimo SafetyNet and UH’s experience using Masimo SafetyNet to help combat COVID-19. The webinar will cover best practices for deploying Masimo SafetyNet, based on UH’s input and deployment of the platform, including the protocols they developed for their teams to integrate it into their response efforts. Clinicians and hospital staff worldwide are invited to participate and learn how they can deploy Masimo SafetyNet at their own institutions. Click here for more details and to register.

Masimo SafetyNet uses a tetherless, wearable single-patient-use SET® sensor to monitor a patient’s blood oxygen saturation and respiration rate, as well as pulse rate, perfusion index, and PVi®, and is designed to help manage the surge in COVID-19 patients while maintaining distance from other patients and providers, allowing hospitals to expand patient remote monitoring into alternative care spaces, including overflow locations, emergency recovery facilities, and home care settings.

The telehealth solution combines clinically proven Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with a cloud-based remote data capture and surveillance platform accessible from a patient’s Android or iOS smartphone or smart device. Monitoring key physiological data can help provide clinicians with an accurate snapshot of a patient’s respiratory status and facilitates awareness of the need for intervention.

“Many patients come to the hospital with COVID-19 symptoms and often times they are admitted simply because clinicians feel the patient would not be safe at home without regular monitoring,” explained Peter Pronovost, MD, Chief Clinical Transformation Officer at University Hospitals in Cleveland, Ohio. “As such, many patients are admitted where they can potentially expose other patients and the staff to the coronavirus. With Masimo SafetyNet, we can now send patients home with the security of the patient and their provider knowing their critical vital signs such as oxygen saturation and respiration rate will be safely monitored at home. This technology also serves as a cost-effective way to scale monitoring and increase capacity for hospitals. We are currently using the product in the following ways: if a patient comes to the emergency department, but can be monitored at home rather than admitted; for patients who are discharged from the hospital and would still benefit from home monitoring; for patients being cared for by home health providers; and for cancer patients with COVID who would be at greater risk if cared for in an inpatient setting. And daily our clinicians are thinking of new ways to apply this technology.”

Aldo Carmona, MD, St. Luke’s Senior Vice President of Clinical Innovation and Chairman of the Department of Anesthesia and Critical Care, added, “I believe the collaboration of the St Luke’s and Masimo teams during our pilot of Masimo SafetyNet will improve the patient and provider experience. In conjunction with the Masimo team, we created a dashboard where multiple patients can be monitored in real time. This can be done rapidly on a floor where no previous monitoring existed and can be monitored from any location; alerts can go to providers in real time. After several years of using the Masimo Patient SafetyNet™ hard-wired system to help improve outcomes, Masimo SafetyNet was a natural solution for our network to meet capacity challenges during this pandemic.”

In addition to COVID-19 CarePrograms, Masimo SafetyNet can be configured for more than 150 other CarePrograms, including COPD, heart failure, and oncology.

Joe Kiani, Founder and CEO of Masimo, said, “Masimo is proud to be able to support the brave nurses and doctors working around the clock to save lives across the world. We believe Masimo SafetyNet is a key asset in the fight against COVID-19, helping clinicians care for the extraordinary surge of patients as efficiently and effectively as possible, both in and out of the hospital. We are grateful for our partnerships with University Hospitals and St. Luke’s, whose piloting and early adoption of Masimo SafetyNet is already showing how this solution is making a difference. Everybody from UH, St Luke’s, and Masimo has worked very hard over the past four weeks to improve the interface so that everyone can now benefit. In addition, we would like to thank our suppliers, Nordic Semiconductor and Texas Instruments, for prioritizing our orders of Masimo SafetyNet components, in volume, to help COVID-19 patients during this difficult time.”

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-6 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,7 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.8 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  2. Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  3. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  4. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  5. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  6. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  7. Estimate: Masimo data on file.
  8. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SafetyNet™ and SET®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo SafetyNet and SET®, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contacts

Masimo
Evan Lamb

949-396-3376

elamb@masimo.com

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.